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Abstract: Vascular oxidative stress has been shown to be a potent factor in the pathophysiology 
of endothelial dysfunction. Despite current optimal evidence-based therapy, mortality from 
various cardiovascular disorders remains high. The search for newer, novel ways of attenuating 
endothelial dysfunction has yielded several new and exciting possibilities, one of which is 
the manipulation of urate levels using xanthine oxidase inhibitors. Agents such as allopurinol 
have shown marked improvements in vascular endothelial function in various cohorts at risk 
of cardiovascular events. Most of the evidence so far comes from smaller mechanistic studies. 
The few large randomized controlled trials have failed to show any significant mortality benefit 
using these agents. This article highlights the potential avenues of further research such as 
dose-response, and the potential for these agents to regress left ventricular hypertrophy. The role 
of newer agents such as febuxostat and oxypurinol are discussed as well as potential reasons 
why some of the current newer agents have failed to live up to the promising early-phase data. 
It is crucial that these remaining questions surrounding urate, xanthine oxidase and the role of 
various agents that affect this important oxidative stress-generating system are answered, and 
therefore these promising agents should not be discarded prematurely.
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Introduction
The adverse effects of oxidative stress on the vascular endothelium have been extensively 
studied in the past.1–5 The major reactive oxygen species (ROS) producing enzyme 
systems are the nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) 
oxidase and xanthine oxidase (XO) systems. The most potent inducer of NADPH 
oxidase is angiotensin II.6,7 The use of angiotensin converting enzyme (ACE) inhibitors 
and angiotensin receptor blockers (ARB) are widespread in medicine for hypertension, 
post-mycardial infarction remodeling, proteinuria as well as heart failure. Much less 
attention has been paid to the XO system despite the availability of new and established 
XO inhibitors such as oxypurinol, febuxostat and allopurinol. The mechanism by which 
XO catalyzes hypoxanthine and xanthine conversion is extremely complex and have 
been previously described in detail.8,9 A fully reduced XO contains 6 electrons and its 
re-oxidation involves electron transfer to oxygen molecules which generates 2 hydro-
gen peroxide (H2O2) and 2 superoxide anion (O2
–) species9 for every fully reduced XO 
molecule. There have been many studies looking at the role of urate and urate-lowering 
agents on endothelial function.10–16 Our group have shown in the past that the improve-
ment in endothelial function seen with allopurinol is due to its ability to inhibit xanthine 
oxidase, and therefore ROS that are produced as a by-product of urate formation. Urate, Therapeutics and Clinical Risk Management 2009:5 800
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therefore, is likely to be a marker of XO activity rather than a 
culprit per se.10 Although there are exciting prospects for the 
improvement of endothelial dysfunction using XO inhibitors 
in high risk cohorts, most of these have come from small 
mechanistic studies.
The question that needs to be addressed now is: how do 
we proceed from here in this area of research so that the full 
therapeutic potential of XO inhibitors can be realized? There is 
clearly some mileage in these agents that needs to be exploited 
further and these agents should not be prematurely discarded. 
This article hopes to stimulate discussion and highlight several 
new possibilities for further study that could potentially clarify 
some of the unresolved issues about to the roles that allopurinol, 
urate and XO play in vascular biology.
Further dose-ranging studies
The importance of dose-response studies cannot be under-
estimated. This is true even for established treatments such 
as ACE inhibitors and ARBs. For example, through unusual 
means of studies in patients who have taken overdoses of 
ACE inhibitors, it has been discovered that much more blood 
pressure lowering can be achieved by the use of doses higher 
than in normal clinical use.17 At the same time other groups 
have shown that ultra-high doses of ARBs, which also act 
on the renin-angiotensin system, have very little additional 
blood pressure lowering over standard doses but may exert 
other beneficial effects on target organs.18
Our mechanistic dose-response studies10 were the first to 
demonstrate that high-dose allopurinol (600 mg/day) reduces 
vascular oxidative stress in congestive heart failure (CHF) 
significantly more than conventional doses (300 mg/day). 
The question remains whether or not even higher doses 
would provide a further improvement on endothelial function. 
A careful study into methods employed by various trials using 
allopurinol in early pharmacokinetic data19,20 and in vivo 
studies measuring XO21 reveals that the oxypurinol concentra-
tion achieved by 600 mg of allopurinol is 9.56 mg/L.19 Taking 
into account the molecular weight of allopurinol (136 g/mol), 
this equates to a concentration of 0.07 mmol/L. Preliminary 
experiments by Spiekermann et al,21 have shown that plasma 
XO activity in vivo is completely inhibited by an oxypurinol 
concentration of 0.1 mmol/L. Interestingly, there has also 
been pharmacokinetic data on 900 mg/day allopurinol which 
achieves in vivo concentrations of 0.09 mmol/L.19 This means 
that 900 mg of allopurinol could almost completely inhibit 
XO activity. How this inhibition will affect overall purine 
metabolism is not yet clear. These initial studies were done 
in fit, healthy males aged 21 to 26 years of age with normal 
renal function. It nevertheless shows that there is further 
potential for oxidative stress reduction at even higher doses. 
Elderly patients, on the other hand, tend to demonstrate 
higher oxypurinol concentrations possibly due to reduced 
renal clearance of oxypurinol and a diminished volume of 
distribution but a lower level of XO inhibition per dose of 
allopurinol20 therefore making them more susceptible to side 
effects. However, further careful dose-ranging studies up to 
900 mg/day of allopurinol could be informative.
Left ventricular hypertophy (LVH) 
regression
Chronic treatment with allopurinol has been shown to 
prevent adverse LV remodeling, decrease LV weight and 
reduce LV collagen density in animal models with heart 
failure.22 It is well known from Framingham23 and from a 
meta-analysis of 48,545 individuals by Vakili et al24 that 
LVH independently confers high cardiac risk, irrespective 
of blood pressure. After age, LVH is said to be the strongest 
independent predictor of cardiovascular (CV) events, 
CV deaths and total mortality.25 LVH is thought to be a culprit 
for 4 reasons: it is intrinsically arrhythmogenic, reduces 
coronary perfusion reserve,26 and it causes diastolic heart 
failure and left atrial dilatation leading to atrial fibrillation 
(AF) and embolic strokes.
Despite a “normal” blood pressure, LVH confers the same 
extra risk in normotensives as it does in hypertensives.27 
Nevertheless, we know that regressing LVH irrespective of 
blood pressure changes is an effective way to reduce risk.28,29 
Furthermore, in the Losartan Intervention for Endpoint 
Reduction in Hypertension (LIFE) Study, LVH regression 
reduced CV events/mortality independent of blood pressure. 
In LIFE, losartan reduced both LVH and CV events more 
than atenolol despite their both reducing blood pressure 
equally. LVH regression reduced incidence of new-AF, 
new onset diabetes, HF hospitalization, sudden deaths and 
strokes.30–32
Since controlling BP and using an ACE inhibitor is only 
partially effective at regressing LVH, we now need additional 
ways of regressing LVH. Apart from controlling the BP, the 
other main therapeutic target that we know about and whose 
manipulation should regress LVH is oxidative stress. There 
is now clear evidence that oxidative stress triggers cardio-
myocyte hypertrophy.33,34 If oxidative stress mediates LVH, 
then reducing oxidative stress should be a promising novel 
approach to preventing or regressing LVH.
Since oxidative stress is a key culprit producing LVH, it 
seems sensible to explore therapies which reduce oxidative Therapeutics and Clinical Risk Management 2009:5 801
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stress (other than ACE inhibitors) to see if they also reduce 
LVH. We found allopurinol to be exceptionally potent 
against ROS in that it can abolish endogenous oxidative 
stress in blood vessels that would otherwise be sensitive to 
supra-physiological doses of vitamin C, a well recognized 
scavenger of reactive oxygen species.10,35 Therefore allo-
purinol becomes a prime therapeutic option to see if it can 
regress LVH.
Other therapies which prevent oxidative stress forming 
(like ACE inhibitors) have already been very successful in 
general and in particular ACE inhibitors are known to regress 
LVH. Since allopurinol dramatically improves oxidative 
stress and its consequence, endothelial dysfunction and 
since oxidative stress is a major mediator of LVH, it seems 
sensible to explore whether allopurinol will also regress LVH. 
We are currently exploring this possibility in optimally treated 
patients with LVH using magnetic resonance imaging.
We have also found that allopurinol significantly reduces 
augmentation index (27.6 ± 3.4% to 20.1 ± 2.2% P  0.05) 
which implies reduced LV afterload.11 Falls in augmentation 
index have been shown to be the best predictor of falls in 
LV mass because augmentation index correlates with LV 
afterload.36 The idea that allopurinol reduces LV afterload is 
confirmed also by the fact that allopurinol reduces B-type 
natriuretic peptide which is a measure of intracardiac 
pressure.37 We are currently investigating the effects of allo-
purinol on LVH and arterial stiffness using indices of vascular 
stiffness and cardiac magnetic resonance.
Febuxostat
Although allopurinol is a very efficiently absorbed drug, it 
is a relatively weak inhibitor of XO with IC50 concentrations 
of between 0.2 and 50 µM.38 Febuxostat [2-[3-cyano-4-
(2-methylpropoxy)phenyl)-4-metylthiazole-5-carboxylic 
acid] is a new non-purine XO inhibitor, which has a higher 
bioavailability and a more potent XO inhibitory effect than 
allopurinol.38 It would therefore theoretically be more effective 
than allopurinol in lowering urate. It also has the advantage 
of being metabolized mainly by glucuronide formation and 
oxidation in the liver39 which would make it a better choice of 
XO inhibitor than patients with renal disease. It is currently 
licensed by both the US Food and Drug Administration (FDA) 
as well as the European Medicines Agency (EMEA) for use 
in chronic hyperuricemia. However, in clinical trials, it did 
not reduce the frequency of attacks of gout,39 it is not as well 
tolerated as allopurinol40 and it possibly increased mortality 
compared to allopurinol.41 Once again, a dose ranging study 
of similar design will be able to identify a dose of febuxostat 
at which oxidative stress is effectively inhibited using this 
newer agent. Comparisons between febuxostat and allopuri-
nol can then be made for a similar degree of urate lowering. 
This agent is potentially a more powerful antioxidant than 
allopurinol given its pharmacokinetic interactions with XO 
and therefore could be studied more closely to ascertain the 
full range of its potential therapeutics benefits.
Oxypurinol
The most high profile XO inhibitor of  late has been oxypurinol. 
Oxypurinol, also known as alloxanthine, is the active 
metabolite of allopurinol. It is licensed for the treatment of 
chronic hyperuricemia by the FDA. Unfortunately, oxypurinol 
research, particularly since the OPT-CHF trial,42 has almost 
ground to a halt. The OPT-CHF trial was a randomized 
controlled trial of oxypurinol 600 mg/day versus placebo in 
405 patients with NYHA Class III and IV heart failure on 
optimal medical therapy. Allopurinol is theoretically less 
potent than oxypurinol because during its conversion to 
oxypurinol, it serves as a substrate for oxygen reduction 
to O2
–. This makes it an initial source of O2
– generation.43,44 
Allopurinol inhibition of O2
– production from XO requires 
both its oxidation to oxypurinol and stabilization of the 
oxypurinol–XO complex.45 In vitro studies also suggest that 
oxypurinol is a more potent OH– scavenger46 and improves 
mechanoenergetic coupling in animal heart failure models.47 
Although two recent high profile studies, EXOTIC-HF 
and LA PLATA using oxypurinol, have demonstrated a 
significant improvement in left ventricular ejection frac-
tion (3.3% and 3.6% respectively) in the acute setting, the 
subsequent OPT-CHF trial also using oxypurinol chroni-
cally for a 6-month duration failed to produce significant 
clinical improvements in unselected patients.48,49 There are 
many reasons that one could speculate on the reasons of the 
OPT-CHF trial outcome such as the efficacy of the oxypuri-
nol dose used50 but the researchers must be given credit for 
taking on this area and attempting to answer an important 
question in a high risk cohort to which a clear answer does 
not exist to this day.
However, OPT-CHF was a small study looking at an 
efficacy endpoint which was a composite that incorporated 
measures of patient outcome and well-being. It was not 
powered for a mortality analysis. A subsequent retrospec-
tive analysis suggests that a subgroup of patients with high 
baseline urate (0.57 mmol/L) might benefit.49 In theory, 
oxypurinol should be preferable to allopurinol in inhibiting 
XO as the metabolism of allopurinol into oxypurinol itself 
generates O2
–.43 Data from the oxypurinol bioequivalence Therapeutics and Clinical Risk Management 2009:5 802
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AAI-US-175 study showed that 600 mg oxypurinol had a 
relative bioavailability equivalent to only 81 mg allopurinol.51 
Therefore it is possible that patients on OPT-CHF were 
underdosed for an effect to be seen as most studies showing 
benefit of allopurinol have used at least 300 mg/day.
Heparin interaction
XO is bound to the surface of endothelial cells by 
glycosaminoglycans and is released following displacement 
by bolus injections of heparin. Relatively low doses (50 iu/kg 
body weight) result in a threefold rise of XO levels in healthy 
volunteers.52 This is the basis of various in vivo experiments 
looking at levels of XO expression. The clinical implica-
tions of this could be enormous as heparin is widely used in 
patients with acute cardiovascular complications. Does this 
mean that patients with an acute coronary syndrome who 
are being treated with heparin require concomitant treatment 
with a XO inhibitor like allopurinol to reduce the burden of 
oxidative stress? Do low-molecular-weight heparins have the 
same effect of XO displacement from glycosaminoglycans 
as unfractionated heparin? It would be fascinating to now 
do studies exploring these issues which could potentially 
be of major clinical importance. Therefore, a double-blind, 
placebo-controlled study of allopurinol in acute coronary 
syndrome patients treated with heparin is needed.
Conclusion
These potential routes forward represent an exciting 
challenge for researchers in vascular biology. They will help 
further clarify the possible role of allopurinol or other agents 
discussed in this article in managing patients who remain at 
risk despite current evidence-based treatments.
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